Explore every aspect of life with kidney disease
A systematic review comparing multiple anti-osteoporosis medications for postoperative re-fracture, hip BMD, and function/pain after hip fragility fracture found time- and outcome-specific…
A systematic review including two randomized controlled trials found teriparatide to be associated with improvements in bone mineral density, but the evidence and safety data remain…
結論：不成立。大型隨機試驗與系統性回顧顯示，對一般社區成人人手吃維生素 D，整體並不能明確降低骨折風險[1][2][3]，只在嚴重缺乏族群或特殊高風險者才可能有幫助。
不成立。雙磷酸鹽整體可降低骨折風險，雖長期使用略增少見「非典型股骨骨折」，但現有證據顯示，多數高風險病人仍是利大於弊。
About 1 in 3 women and 1 in 5 men over 50 will suffer an osteoporotic fracture; hip fracture carries ~20% one-year mortality.
雙磷酸鹽（alendronate、zoledronate）與 denosumab 會抑制骨頭代謝，極少數人在拔牙或植牙後出現顎骨壞死（MRONJ）。美國口腔顎面外科學會 2022 年立場文件：骨質疏鬆患者的風險約 0.02–0.05%（每萬人 2–5 例），denosumab 用滿 10 年約 0.3%；癌症患者用高劑量針劑則達 1–5%、拔牙後可到…
對一般社區長者不成立。JAMA 2017 統合分析（33 個隨機試驗、51,145 名 50 歲以上社區居民）：鈣片、維生素 D 或兩者合併，髖部、脊椎、非脊椎與總骨折風險都沒有顯著降低；BMJ 2015 系統性回顧：飲食鈣攝取量與骨折無關，鈣片在偏誤風險最低的試驗中對任何部位骨折都無效，而且每千人服鈣片會多出腎結石與腸胃住院。美國 USPSTF…
Add Beyond CKD to your home screen
Open it like an app, and read articles and tools you have visited even when offline.